$heff's $tation of $tocks & $olid DD

[rocketeer357]

MTNB out with positive news/small sample results:

http://www.matinasbiopharma.com/media/press-releases/detail/293/matinas-biopharma-announces-interim-data-from-nih-conducted

“We are incredibly pleased with the interim safety and efficacy results of this Phase 2a study of MAT2203. While we understand the results are representative of just two patients, these patients are difficult to treat because of their severe underlying immunocompromising condition. With the statistical success hurdle that was prospectively set at a 20% patient-response probability, seeing a clinical response in two out of two patients brings us very close to the 3 out of 16 clinical responders required for the study to meet its primary endpoint, “ said Roelof Rongen, Chief Executive Officer.

As expected, oral thrush promptly returned after stopping treatment with MAT2203. Therefore, Matinas’ preliminary clinical data indicate that MAT2203 is promising as an oral systemically-absorbed broad-based antifungal without the toxicity of parenteral amphotericin B.

CC Monday, June 5, 2017 at 8:30 a.m. ET